Trial reportThorax1998
Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects.
Trial report in Thorax, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 57 citations in OpenAlex.
- Salbutamol but not ipratropium abolishes leukotriene D4-induced gas exchange abnormalities in asthma.European journal of clinical pharmacology · 2012Trial
- Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma.Thorax · 2006Trial
- Well-controlled mucosal exudation of plasma proteins in airways with intact and regenerating epithelium.Physiological reports · 2024Review
- Humoral First-Line Mucosal Innate Defence in vivo.Journal of innate immunity · 2020Review
- Airways exudation of plasma macromolecules: Innate defense, epithelial regeneration, and asthma.The Journal of allergy and clinical immunology · 2019Review
- Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma.Respiratory research · 2011Article
- Receptor-mediated enhancement of beta adrenergic drug activity by ascorbate in vitro and in vivo.PloS one · 2010Article
- The role of the bronchial microvasculature in the airway remodelling in asthma and COPD.Respiratory research · 2010Review
- Role of arformoterol in the management of COPD.International journal of chronic obstructive pulmonary disease · 2008Review
- Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.British journal of pharmacology · 2007Article
- Benefit-risk assessment of long-acting beta2-agonists in asthma.Drug safety · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of studies have shown that beta 2 agonists, including formoterol, inhibit plasma exudation induced by the inflammatory stimulus in animal airways. Whether clinical doses of beta 2 agonists inhibit plasma exudation in human bronchial airways is unknown.
methodsIn order to explore the microvascular permeability and its potential inhibition by beta 2 agonists in human bronchial airways a dual induction method was developed: plasma exudation induced by histamine inhalation followed by sputum induction by hypertonic saline (4.5%) inhalation. Sixteen healthy subjects received formoterol (18 micrograms) in a placebo controlled, double blind, crossover study. Sputum was induced on five occasions: once at baseline and four times after histamine challenge (30 minutes and eight hours after both formoterol and placebo treatments). Sputum levels of alpha 2-macroglobulin were determined to indicate microvascular-epithelial exudation of bulk plasma.
resultsHistamine induced plasma exudation 30 minutes after placebo was considerably greater than at baseline (median difference 11.3 micrograms/ml (95% confidence interval 0.9 to 90.0)). At 30 minutes after formoterol the effect of histamine was reduced by 5.1 (0.9 to 61.9) micrograms/ml compared with placebo. At eight hours histamine produced less exudation and inhibition by formoterol was not demonstrated.
conclusionThis study shows for the first time an anti-exudative effect of a beta 2 agonist in healthy human bronchial airways. Through its physical and biological effects, plasma exudation is of multipotential pathogenic importance in asthma. If the present findings translate to disease conditions, it suggests that an anti-exudative effect may contribute to the anti-asthmatic activity of formoterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.